ADCS

Antaris Accelerates Space Technology with More Customers Using the Antaris Cloud Platform and JANUS-2 Launch on the Horizon

Retrieved on: 
Wednesday, February 21, 2024
Cloud, LOS, Internet of things, Growth, Communication, Quantum key distribution, SDK, GitHub, EPS, Hardware abstraction, ADCS, HAL, Video game

LOS ALTOS, Calif., Feb. 21, 2024 /PRNewswire/ -- Antaris, the leading software platform for space missions, had a pivotal 2023, launching its first demonstration satellite, raising additional capital, expanding its customer base, and solidifying its position as an innovative player in the space industry.

Key Points: 
  • In February 2023, Antaris marked a historic moment with the successful launch and operation of JANUS-1, the world's first satellite to be designed and tested entirely in the cloud.
  • In September 2023, Antaris closed its seed funding round with an additional $3.5 million, led by California-based Streamlined Ventures.
  • Throughout the year, Antaris also demonstrated its commitment to open-source development for the benefit of the entire space industry.
  • Currently, Netra is utilizing every part of the Antaris Cloud Platform: the Antaris Design Studio, the TrueTwin™ simulation environment, and the SatOS™ payload SDK.

SpecterOps Adds Industry-Leading Protection for Active Directory Certificate Services to BloodHound Enterprise

Retrieved on: 
Tuesday, January 9, 2024
Networks, Security, Data Management, Technology, Software, BHE, Early access, Moses Austin, Research, Woodside Energy, Microsoft, University, IAM, Public key infrastructure, Active Directory, Risk, Environment, Acquisition, Capital Group Companies, ADCS, Access, Cryptocurrency

SpecterOps , a provider of adversary-focused cybersecurity solutions and unique insights of advanced threat actor tradecraft, today announced updates to BloodHound Enterprise (BHE) that add new Attack Paths focused on Active Directory Certificate Services (ADCS).

Key Points: 
  • SpecterOps , a provider of adversary-focused cybersecurity solutions and unique insights of advanced threat actor tradecraft, today announced updates to BloodHound Enterprise (BHE) that add new Attack Paths focused on Active Directory Certificate Services (ADCS).
  • ADCS is the Public Key Infrastructure implementation of Microsoft Active Directory and is widely used in enterprise environments including most of the Fortune 1000.
  • They discovered many common misconfigurations in enterprise ADCS environments that allow attackers to steal certificates, achieve account persistence, and achieve full control over an Active Directory domain.
  • BloodHound Enterprise (BHE) is the industry’s first platform for comprehensively removing identity attack paths in Microsoft’s Active Directory (AD) and Entra/Azure AD.

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023
Patient, FDA, Research, Gian Maria Annovi, Standard of care, Kinetics, AD, PD, Patent, III, II, Human, Neurodegenerative disease, ADCS, Axonal transport, News, Conference, CNS, Inflammation, Data, PHL, ThinkEquity, Mouse, AAIC, American City Business Journals, Neurology, University of Washington School of Medicine, University, Brain, Safety, Movement, European, Death, Communication, Cognition, DSMB, Pharmaceutical industry, Vaccine, Cryptocurrency, Palladium

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose

Retrieved on: 
Monday, October 23, 2023
Alzheimer's Disease Cooperative Study, Element, Cognition, Plasma, Euronext Amsterdam, AD, Alzheimer's disease, ADCS, BID, Skin, Hepatology, OLE, European, Probability, University, VIVA, Safety, Therapy, Patient, Memory, DSMB, Pharmaceutical industry, Neuroscience

VIVA-MIND (NCT03919162) is an ongoing Phase 2 study for varoglutamstat conducted in the U.S., complementary to Vivoryon’s VIVIAD Phase 2b study being conducted in Europe.

Key Points: 
  • VIVA-MIND (NCT03919162) is an ongoing Phase 2 study for varoglutamstat conducted in the U.S., complementary to Vivoryon’s VIVIAD Phase 2b study being conducted in Europe.
  • The primary endpoint of the study is evaluating Clinical Dementia Rating scale Sum of Boxes (CDR-SB) over a 72-week treatment period.
  • “We are thrilled to report this new important and validating element of our rigorously and meticulously designed program for varoglutamstat.
  • Vivoryon remains on track to report the final data readout from the VIVIAD study in the first quarter of 2024.

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 15, 2023
Mental Health, Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Xchange, Cognition, Axonal transport, Patent, Human, University, Gian Maria Annovi, PD, Senior, AE, DSMB, Bio, Neurodegenerative disease, Trial of the century, Brain, Inflammation, CNS, University of Washington School of Medicine, Thought, Movement, II, Research and development, Development, AAIC, TDP43, Patient, Data, European, ADCS, Mouse, Poster, AD, FDA, Therapy, Death, III, Memory, NYSE, News, Conference, Safety, Kinetics, Pharmaceutical industry, Tutoring, Cryptocurrency, Palladium, Buntanetap

Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced second quarter financial results for the period ended June 30, 2023, and reviewed recent accomplishments.
  • On June 3, Annovis announced it had reached full enrollment in the trial in a record nine months.
  • The planned enrollment has been achieved and based on this DSMB endorsement, Annovis expects topline results by the end of 2023.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Retrieved on: 
Friday, July 7, 2023
Amyloid-related imaging abnormalities, Insurance, Disease, CMS, Clinical trial, PCNS, The New England Journal of Medicine, Deficit spending, Research, Today, MCI, Neurotoxicity, Committee, Medicare, Clarity, ARIA, HIV disease progression rates, Patient, Immunoglobulin G, Co-promotion, Diagnosis, Lecanemab, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, ADCS, Conditional sentence, Pharmaceutical industry, Alzheimer's disease, Biogen, Eisai

Treatment with LEQEMBI should be initiated in patients with MCI or mild dementia stage of disease, (collectively referred to as early AD) the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with LEQEMBI should be initiated in patients with MCI or mild dementia stage of disease, (collectively referred to as early AD) the population in which treatment was initiated in clinical trials.
  • LEQEMBI treatment reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • Importantly, following FDA's traditional approval of LEQEMBI, CMS confirmed that broader coverage of LEQEMBI is now available and released more details on the registry, including the easy-to-use data submission process.
  • "Today, the FDA approved LEQEMBI under the traditional approval pathway, making LEQEMBI the first and only approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease.

Outpost Appoints Eric Wostenberg as New Vice President of Engineering

Retrieved on: 
Monday, August 7, 2023
FRAM, M&P, Computer, Outpost, Falcon, Vehicle engineering, NASA, Virgin Orbit, SpaceX, LauncherOne, ADCS, Renewable energy, Communications satellite, Engineering, Dragon, Gas-pak

SANTA MONICA, Calif., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Outpost, the sustainable space company, announced today that Eric Wostenberg has joined its executive team as Vice President of Engineering to lead all engineering efforts. Wostenberg takes the helm of engineering at Outpost as the company prepares for its second satellite launch, and continues advancement in development of its returnable satellite.

Key Points: 
  • SANTA MONICA, Calif., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Outpost, the sustainable space company, announced today that Eric Wostenberg has joined its executive team as Vice President of Engineering to lead all engineering efforts.
  • Wostenberg takes the helm of engineering at Outpost as the company prepares for its second satellite launch, and continues advancement in development of its returnable satellite.
  • A storied leader with more than 15 years of experience in aerospace engineering across startups and hyper-scale companies, Wostenberg has a proven track record in leading and scaling critical engineering programs at companies on the cutting edge of space exploration.
  • In only 7 months, Outpost built two flight model satellites featuring in-house designed, and built power systems, communications, computers, harnessing and ADCS.

Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference

Retrieved on: 
Tuesday, July 18, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Cognition, Axonal transport, Neuron, Human, University, PD, Bio, Neurodegenerative disease, Trial of the century, Brain, Inflammation, Neurotoxicity, Movement, University of Washington School of Medicine, II, AAIC, Protein, Clinical trial, Patient, Nervous system, Mouse, APP, AD, III, Conference, NYSE, Mutation, ADCS, Kinetics, Pharmaceutical industry, Vaccine, Medical device, Buntanetap

Annovis’ drug acts through a novel mechanism of action that inhibits all the major neurotoxic proteins responsible for AD and PD even before they are produced.

Key Points: 
  • Annovis’ drug acts through a novel mechanism of action that inhibits all the major neurotoxic proteins responsible for AD and PD even before they are produced.
  • This contrasts with other companies’ AD and PD drugs which remove only one of the toxic proteins after it is produced.
  • The combined findings from the posters tell the story of an exceptionally promising treatment for neurodegenerative disease such as AD and PD.
  • Cheng Fang , Ph.D., senior vice president of research and development at Annovis Bio, presented two posters at AAIC.

Tensor Tech Disrupting Satellite Minimization by Going Lighter, Smaller, and More Power-Efficient

Retrieved on: 
Friday, March 31, 2023
Small satellite, Partnership, Travel, Calibration, CMG (company), Space, Government, Space Foundation, CMG, Hearing, Growth, Conference, ADCS, Renewable energy, Communications satellite, Fine chemical, Video game

NEW TAIPEI CITY, Taiwan, March 31, 2023 /PRNewswire/ -- Tensor Tech , a Taiwan-based company specializing in satellite minimization, is pushing to disrupt the booming worldwide space industry with lighter, smaller, and more power-efficient satellite subsystems.

Key Points: 
  • NEW TAIPEI CITY, Taiwan, March 31, 2023 /PRNewswire/ -- Tensor Tech , a Taiwan-based company specializing in satellite minimization, is pushing to disrupt the booming worldwide space industry with lighter, smaller, and more power-efficient satellite subsystems.
  • The costs involved represent a prime opportunity for companies like Tensor Tech to step in and assist on a variety of government and commercial space ventures.
  • A possible workaround is that of satellite minimization, but the ADCS is the biggest roadblock among all other subsystems .
  • Tensor Tech will be making appearances in several upcoming events, including the Small Satellite Conference 2023 and Space Tech Expo Europe 2023 .